TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07509151: A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocyti

Sponsor: AstraZeneca · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 420 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$20,402,844

Rescue Site Savings

+$13,448,820

Unlock Full NCT07509151 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07509151 Rescue Dossier →